Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
Back

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

Not Recruiting

Open to: ALL

Age: 18.0 - N/A

London Stevenage Scunthorpe Edinburgh Sheffield London London Truro Plymouth

Medical Conditions

Urinary Bladder Neoplasms
Non-Muscle Invasive Bladder Neoplasms

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS), between TAR-200 plus cetrelimab (Group A) and TAR-200 alone (Group C) versus intravesical BCG (Group B).

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Mar 2023 Sep 2029

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : TAR-200 will be administered intravesically.

Intervention Arm Group : Treatment Group A: TAR-200 + Cetrelimab;Treatment Group C: TAR-200 Alone;

Intervention Type : BIOLOGICAL
Intervention Description : Cetrelimab will be administered.

Intervention Arm Group : Treatment Group A: TAR-200 + Cetrelimab;

Intervention Type : BIOLOGICAL
Intervention Description : BCG will be administered intravesically.

Intervention Arm Group : Treatment Group B: Bacillus Calmette-Guerin (BCG) Vesiculture;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Charing Cross Hospital
    London
    W6 8RF
  • Lister Hospital
    Stevenage
    SG1 4AB
  • Scunthorpe General Hospital
    Scunthorpe
    DN15 7BH
  • Western General Hospital
    Edinburgh
    EH4 2XU
  • Sheffield Teaching Hospitals NHS Foundation Trust
    Sheffield
    S10 2JF
  • St Bartholomews Hospital
    London
    EC1A 7BE
  • The Royal Marsden NHS Trust
    London
    SW3 6JJ
  • Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital
    Truro
    TR1 3LJ
  • Derriford Hospital
    Plymouth
    PL6 8DH


The study is sponsored by Janssen Research & Development, LLC



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05714202
Last updated 22 May 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top